Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Clene (Nasdaq: CLNN) said management will participate in a panel discussion at the Maxim Growth Summit and will host 1x1 investor meetings on October 22, 2025 in New York City. The panel is titled Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Meeting requests for 1x1 sessions are available through a Maxim representative.
The company and its subsidiary Clene Nanomedicine focus on mitochondrial health and neuronal protection for diseases including ALS and MS.
Clene (Nasdaq: CLNN) ha detto che la gestione parteciperà a una tavola rotonda al Maxim Growth Summit e ospiterà incontri con investitori 1x1 il 22 ottobre 2025 a New York City. Il pannello è intitolato Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Le richieste di meeting 1x1 sono disponibili tramite un rappresentante di Maxim.
La società e la sua controllata Clene Nanomedicine si concentrano sulla salute mitocondriale e sulla protezione neuronale per malattie tra cui ALS e MS.
Clene (Nasdaq: CLNN) dijo que la dirección participará en un panel de discusión en el Maxim Growth Summit y organizará reuniones de inversionistas 1x1 el 22 de octubre de 2025 en Nueva York. El panel se titula Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Las solicitudes de reuniones 1x1 están disponibles a través de un representante de Maxim.
La empresa y su subsidiaria Clene Nanomedicine se enfocan en la salud mitocondrial y la protección neuronal para enfermedades que incluyen ALS y MS.
Clene (Nasdaq: CLNN) 경영진은 Maxim Growth Summit의 패널 토론에 참여하고 2025년 10월 22일에 뉴욕시에서 1대1 투자자 미팅을 주최할 예정이라고 밝혔다. 패널의 제목은 Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories이다. 1대1 세션 요청은 Maxim 담당자를 통해 가능하다.
이 회사와 그 자회사 Clene Nanomedicine은 미토콘드리아 건강과 신경 보호에 초점을 맞추고 있으며 ALS 및 MS를 포함한 질환을 대상으로 한다.
Clene (Nasdaq: CLNN) a déclaré que la direction participera à une table ronde lors du Maxim Growth Summit et organisera des réunions investisseurs 1x1 le 22 octobre 2025 à New York. La table ronde est intitulée Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Les demandes de réunions 1x1 sont disponibles par l’intermédiaire d’un représentant de Maxim.
La société et sa filiale Clene Nanomedicine se concentrent sur la santé mitochondriale et la protection neuronale pour des maladies telles que ALS et MS.
Clene (Nasdaq: CLNN) sagte, dass das Management an einer Podiumsdiskussion beim Maxim Growth Summit teilnehmen und am 22. Oktober 2025 in New York City 1-zu-1-Investorengespräche durchführen wird. Das Panel trägt den Titel Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. Anfragen für 1x1-Sitzungen sind über einen Maxim-Vertreter erhältlich.
Das Unternehmen und seine Tochtergesellschaft Clene Nanomedicine konzentrieren sich auf mitochondriale Gesundheit und neuronalen Schutz bei Erkrankungen, zu denen ALS und MS gehören.
Clene (Nasdaq: CLNN) قالت الإدارة إنها ستشارك في حلقة نقاش في Maxim Growth Summit وستستضيف اجتماعات استثمارية 1x1 في 22 أكتوبر 2025 في مدينة نيويورك. الحلقة الحوارية بعنوان Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories. طلبات الاجتماعات 1x1 متاحة من خلال ممثل ماكسيم.
تركّز الشركة وشركتها الفرعية Clene Nanomedicine على صحة الميتوكوندريا وحماية الأعصاب لأمراض تشمل ALS و MS.
Clene (Nasdaq: CLNN) 表示管理层将参加 Maxim Growth Summit 的小组讨论，并将在 2025年10月22日 在 纽约市 主办1对1投资者会谈。该小组的题目是 Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories。通过 Maxim 代表可提出1对1会议的请求。
该公司及其子公司 Clene Nanomedicine 专注于线粒体健康和神经保护，涉及疾病包括 ALS 和 MS。
- None.
- None.
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a panel discussion at the Maxim Growth Summit and host 1x1 investor meetings.
Date: October 22, 2025
Location: New York City, NY
Panel Discussion: Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutic Categories
1x1 Meetings: Please contact your Maxim representative
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Clene (CLNN) participate in the Maxim Growth Summit?
What panel will Clene (CLNN) join at the Maxim Growth Summit?
How can investors request 1x1 meetings with Clene (CLNN) at the Maxim Growth Summit?
Which Clene subsidiaries are referenced for the Maxim Growth Summit appearance?
What therapeutic areas will Clene (CLNN) highlight at the panel on October 22, 2025?
Where is the Maxim Growth Summit session featuring Clene (CLNN) located?
